ATHERSYS INC (ATHX) rated Outperform by Cowen & Co
Cowen & Co rated Outperform ATHERSYS INC (NASDAQ: ATHX) on 06/02/2008, when the stock price was $3.25. Since
then, ATHERSYS INC has lost 64.92% as of 08/27/2015's recent price of $1.14. If you would have followed this Cowen & Co's recommendation on ATHX, you would have lost 64.92% of your investment in 2642 days.
Athersys, Inc., is a biopharmaceutical company engaged in the discovery and development of therapeutic products. Through the application of its technologies, the Company has established a pipeline of therapeutic product development programs in multiple disease areas. The Company?s current product development portfolio consists of MultiStem, a patented and stem cell product that the Company is developing as a treatment for multiple disease indications, and that is being evaluated in two ongoing clinical trials. In addition, the Company are developing novel pharmaceuticals to treat indications such as obesity, certain cognitive and attention disorders, narcolepsy or other forms of excessive daytime sleepiness. In December 2008, the Company were granted authorization by the United States Food and Drug Administration (FDA), to initiate a third clinical trial, administering MultiStem for the treatment of ischemic stroke.
Cowen and Company’s culture is rooted in the traditions of the research boutiques that once dominated the investment research landscape. Our primary focus is on two products:
1. Proprietary information flow, and
2. Good investment ideas
We achieve the first objective with a combination of extensive primary research work, organized survey activity, and access to industry experts (i.e., opinion leaders in medicine, technology, and consumer industries).
We believe that the best investment idea is a “Correct Non-Consensus Conclusion,” and a considerable amount of our energy is devoted to this pursuit. We spend as little time as possible on traditional maintenance research products.